AFSSAPS approves TxCell to extend crohn’s disease drug Phase I/II trial
CATS1 Phase I/II trial intends to investigate the tolerability and efficacy of Ovasave, a type 1 regulatory T cell based immunotherapy, in patients with severe chronic active Crohn’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.